Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scFv-IgG) (BSSG-172)

Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-IL13 antibody variable domain are respectively connected to the N terminus of the anti-IL17 IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Asthma therapy.

Datasheet INQUIRY

Specifications

Targets

IL13 & IL17

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Asthma

Targets

Target 1

IL13

Gene ID

3596

UniProt ID

P35225

Alternative Names

IL13; interleukin 13; P600; IL-13; interleukin-13

Target 2

IL17

Gene ID

3605

UniProt ID

Q16552

Alternative Names

IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; interleukin-17A; CTLA-8; cytotoxic T-lymphocyte-associated antigen 8; cytotoxic T-lymphocyte-associated protein 8; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scFv-IgG) (BSSG-172). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scFv-IgG) (CAT#: BSSG-172)

Specifications

Targets

Customer Reviews and Q&As